GlassScriptPhysician profile
Rakshni Kokilakumar
NPI 1508639220
$7,344.77
in general payments reported to CMS, 2019-2025
26 companies · $4,015 in 2025
The $4,015 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,330 · 2025: $4,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,077 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,076.78 |
| Education | $267.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,118.58 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $818.18 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $781.07 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $747.17 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $655.91 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $610.80 | 2024-2025 | Tremfya |
| Abbvie INC. | $351.17 | 2024-2025 | |
| Lilly USA, LLC | $262.70 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Dermavant Sciences, INC. | $255.22 | 2024 | Vtama |
| Organon LLC | $240.33 | 2024-2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.10 | 2024-2025 | Siliq, Targretin, Duobrii |
| Botanix Sb INC | $192.74 | 2025 | Sofdra |
| Pfizer INC. | $186.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.19 | 2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $133.78 | 2024 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $125.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.72 | 2024-2025 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $89.43 | 2024 | Nuzyra |
| Leo Pharma INC. | $73.02 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $53.65 | 2025 | Otezla |
| Genzyme Corporation | $49.49 | 2025 | |
| Janssen Scientific Affairs, LLC | $47.63 | 2024-2025 | Tremfya |
| Incyte Corporation | $35.95 | 2024 | Opzelura |
| Octapharma USA, INC. | $20.95 | 2024 | Octagam Immune Globulin (Human) |
| Almirall LLC | $19.32 | 2025 | Seysara |
| Becton, Dickinson and Company | $14.98 | 2024 | Venclose Maven Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakshni Kokilakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.